Tukholmankatu 8 A
00290 Helsinki, fi
+358 (400) 569-628
Oncos Therapeutics Raises € 4 Million From Healthcap to Develop Oncolytic Viruses Into Cancer Treatments
After treating 200 late stage cancer patients since 2007 with strong safety and efficacy results, Oncos has selected its modified oncolytic adenovirus CGTG-102 as its lead clinical candidate. "This is the first step to turn our Advanced Therapy Access Program results into cancer therapeutics", comments Pekka Simula, CEO and cofounder.
"The results have been strong for late stage solid tumor cancers where routine therapies have failed. Time is critical in the treatment of cancer. We are confident that when treating earlier stage patients, our oncolytic virus therapy will prove even more significant", continues Research Professor Akseli Hemminki, CSO and cofounder.
"Oncolytic viruses are maturing as a new treatment modality in cancer. Oncos, as one of the leading companies in the field, and combines very promising results in humans with strong science", comments Dr Johan Christensen, partner at HealthCap.
About HealthCap - www.healthcap.se
HealthCap is a family of multi stage venture capital funds, investing globally in life sciences, with the Odlander Fredrikson Group as their exclusive investments advisor. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe. For more information visit: http://www.healthcap.se.
About CGTG-102 engineered oncolytic adenovirus
The oncolytic virus CGTG-102 is the lead candidate of Oncos Therapeutics. This modified oncolytic adenovirus combines the established safety of adenovirus therapies with GM-CSF arming and improved tumor cell transduction via capsid modification. The unique design enables high tumor selectivity, sustained antitumor immune response, bodywide efficacy, and a very acceptable side effect profile. So far, 18 solid tumor cancers and 200 patients - including children - have been treated with CGTG-102, the data suggesting broad applicability across cancer types.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.